ACRV vs. BCYC, IRWD, VRNA, OCUL, GYRE, IMNM, ABVX, CVAC, CNTA, and SPRY
Should you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Bicycle Therapeutics (BCYC), Ironwood Pharmaceuticals (IRWD), Verona Pharma (VRNA), Ocular Therapeutix (OCUL), Gyre Therapeutics (GYRE), Immunome (IMNM), ABIVAX Société Anonyme (ABVX), CureVac (CVAC), Centessa Pharmaceuticals (CNTA), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical preparations" industry.
Bicycle Therapeutics (NASDAQ:BCYC) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, community ranking, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.
Bicycle Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.
Acrivon Therapeutics has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Bicycle Therapeutics had 2 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 4 mentions for Bicycle Therapeutics and 2 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.89 beat Bicycle Therapeutics' score of 0.72 indicating that Bicycle Therapeutics is being referred to more favorably in the media.
86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 8.5% of Bicycle Therapeutics shares are held by insiders. Comparatively, 8.5% of Acrivon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Bicycle Therapeutics received 95 more outperform votes than Acrivon Therapeutics when rated by MarketBeat users. However, 96.15% of users gave Acrivon Therapeutics an outperform vote while only 68.57% of users gave Bicycle Therapeutics an outperform vote.
Acrivon Therapeutics has a net margin of 0.00% compared to Acrivon Therapeutics' net margin of -404.14%. Acrivon Therapeutics' return on equity of -49.35% beat Bicycle Therapeutics' return on equity.
Bicycle Therapeutics currently has a consensus target price of $46.86, indicating a potential upside of 111.16%. Acrivon Therapeutics has a consensus target price of $22.57, indicating a potential upside of 192.38%. Given Bicycle Therapeutics' higher probable upside, analysts plainly believe Acrivon Therapeutics is more favorable than Bicycle Therapeutics.
Summary
Bicycle Therapeutics and Acrivon Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Acrivon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acrivon Therapeutics Competitors List
Related Companies and Tools
